Trial intelligence / Profile preview

Phase II study of gumarontinib for MET exon 14 skipping mutation-positive advanced non-small cell lung cancer with intracranial metastases

jRCTs031260171Phase 2Recruiting

Sponsor

Taiho Pharmaceutical Co., Ltd.

Start

Jun 2026

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

2